Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

NCT03984448 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03984448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03984448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
October 22, 2019
Completion date
April 1, 2028
Enrollment
363 (estimated)
Sites
634

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, diffuse large b-cell lymphoma, not otherwise specified, double-expressor lymphoma, ebv-positive diffuse large b-cell lymphoma, not otherwise specified, high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, neoplastic cells with double expression of myc and bcl2 proteins present, transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma